214 related articles for article (PubMed ID: 37197205)
1. HBV reactivation and its effect on survival in HBV-related hepatocarcinoma patients undergoing transarterial chemoembolization combined with tyrosine kinase inhibitors plus immune checkpoint inhibitors.
Shen J; Wang X; Wang N; Wen S; Yang G; Li L; Fu J; Pan X
Front Cell Infect Microbiol; 2023; 13():1179689. PubMed ID: 37197205
[TBL] [Abstract][Full Text] [Related]
2. Effects of transarterial chemoembolization combined with antiviral therapy on HBV reactivation and liver function in HBV-related hepatocellular carcinoma patients with HBV-DNA negative.
Wang K; Jiang G; Jia Z; Zhu X; Ni C
Medicine (Baltimore); 2018 Jun; 97(22):e10940. PubMed ID: 29851833
[TBL] [Abstract][Full Text] [Related]
3. Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors Versus Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma with First- or Lower-Order Portal Vein Tumor Thrombosis.
Zhang JX; Cheng Y; Wei J; Fan WL; Liu J; Zhou CG; Liu S; Shi HB; Chu XY; Zheng WL; Zu QQ
Cardiovasc Intervent Radiol; 2024 Jun; 47(6):751-761. PubMed ID: 38671322
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Prophylactic Entecavir for Hepatitis B Virus-Related Hepatocellular Carcinoma Receiving Transcatheter Arterial Chemoembolization.
Li X; Zhong X; Chen ZH; Wang TT; Ma XK; Xing YF; Wu DH; Dong M; Chen J; Ruan DY; Lin ZX; Wen JY; Wei L; Wu XY; Lin Q
Asian Pac J Cancer Prev; 2015; 16(18):8665-70. PubMed ID: 26745134
[TBL] [Abstract][Full Text] [Related]
5. Correlation of HBV DNA and Hepatitis B Surface Antigen Levels With Tumor Response, Liver Function and Immunological Indicators in Liver Cancer Patients With HBV Infection Undergoing PD-1 Inhibition Combinational Therapy.
Pan S; Yu Y; Wang S; Tu B; Shen Y; Qiu Q; Liu X; Su N; Zuo Y; Luan J; Zhang JY; Shi M; Meng F; Wang FS
Front Immunol; 2022; 13():892618. PubMed ID: 35711409
[TBL] [Abstract][Full Text] [Related]
6. Comparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitors.
Lei J; Yan T; Zhang L; Chen B; Cheng J; Gao X; Liu Z; Li Y; Zuo S; Lu Y
Hepatol Int; 2023 Apr; 17(2):281-290. PubMed ID: 36580258
[TBL] [Abstract][Full Text] [Related]
7. Reactivation of hepatitis B virus in HBsAg-negative patients with hepatocellular carcinoma.
Jang JW; Kim YW; Lee SW; Kwon JH; Nam SW; Bae SH; Choi JY; Yoon SK; Chung KW
PLoS One; 2015; 10(3):e0122041. PubMed ID: 25894607
[TBL] [Abstract][Full Text] [Related]
8. Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma.
Lao XM; Luo G; Ye LT; Luo C; Shi M; Wang D; Guo R; Chen M; Li S; Lin X; Yuan Y
Liver Int; 2013 Apr; 33(4):595-604. PubMed ID: 23402625
[TBL] [Abstract][Full Text] [Related]
9. Effects of TACE and preventive antiviral therapy on HBV reactivation and subsequent hepatitis in hepatocellular carcinoma: a meta-analysis.
Zhang SS; Liu JX; Zhu J; Xiao MB; Lu CH; Ni RZ; Qu LS
Jpn J Clin Oncol; 2019 Jul; 49(7):646-655. PubMed ID: 30968933
[TBL] [Abstract][Full Text] [Related]
10. Liver Injury and Its Impact on Prognosis in Patients with HBV-Related Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors.
Shen J; Wang X; Yang G; Li L; Fu J; Xu W; Zhang Q; Pan X
J Hepatocell Carcinoma; 2024; 11():207-217. PubMed ID: 38283694
[TBL] [Abstract][Full Text] [Related]
11. [Clinical features and prognostic analysis of transarterial chemoembolization combined with targeted immunotherapy in the treatment of patients with hepatitis B virus-related intermediate-and advanced-stage hepatocellular carcinoma with secondary cholestasis].
Wang NN; Shen JM; Li HL; Wang X; Yang GD; Pan XC; Li J
Zhonghua Gan Zang Bing Za Zhi; 2023 Nov; 31(11):1149-1155. PubMed ID: 38238947
[No Abstract] [Full Text] [Related]
12. Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma.
Lee PC; Chao Y; Chen MH; Lan KH; Lee IC; Hou MC; Huang YH
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32863270
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B virus reactivation in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization therapy.
Peng JW; Lin GN; Xiao JJ; Jiang XM
Asia Pac J Clin Oncol; 2012 Dec; 8(4):356-61. PubMed ID: 22897940
[TBL] [Abstract][Full Text] [Related]
14. Role of Transarterial Chemoembolization in the Era of Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Combination Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score Matched Analysis.
Zhang JX; Hua HJ; Cheng Y; Liu S; Shi HB; Zu QQ
Acad Radiol; 2024 Apr; 31(4):1304-1311. PubMed ID: 37775449
[TBL] [Abstract][Full Text] [Related]
15. Posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV-DNA levels.
Huang G; Lai EC; Lau WY; Zhou WP; Shen F; Pan ZY; Fu SY; Wu MC
Ann Surg; 2013 Mar; 257(3):490-505. PubMed ID: 22868358
[TBL] [Abstract][Full Text] [Related]
16. Changes of HBV DNA After Chemoembolization for Hepatocellular Carcinoma and the Efficacy of Antiviral Treatment.
Lin XJ; Lao XM; Shi M; Li SP
Dig Dis Sci; 2016 Sep; 61(9):2465-76. PubMed ID: 27105647
[TBL] [Abstract][Full Text] [Related]
17. Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma.
Huang JT; Zhong BY; Jiang N; Li WC; Zhang S; Yin Y; Yang J; Shen J; Wang WS; Zhu XL
J Hepatocell Carcinoma; 2022; 9():1217-1228. PubMed ID: 36474670
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B virus reactivation after radiotherapy for hepatocellular carcinoma and efficacy of antiviral treatment: A multicenter study.
Jun BG; Kim YD; Kim SG; Kim YS; Jeong SW; Jang JY; Lee SH; Kim HS; Kang SH; Kim MY; Baik SK; Lee M; Kim TS; Choi DH; Choi SH; Suk KT; Kim DJ; Cheon GJ
PLoS One; 2018; 13(7):e0201316. PubMed ID: 30059513
[TBL] [Abstract][Full Text] [Related]
19. Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV-related hepatocellular carcinoma: report of a prospective study.
Park JW; Park KW; Cho SH; Park HS; Lee WJ; Lee DH; Kim CM
Am J Gastroenterol; 2005 Oct; 100(10):2194-200. PubMed ID: 16181368
[TBL] [Abstract][Full Text] [Related]
20. Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis.
He MK; Peng C; Zhao Y; Liang RB; Lai ZC; Kan A; Li QJ; Wei W; Zhang YJ; Chen MS; Guo RP; Shi M
Cancer Immunol Immunother; 2021 Nov; 70(11):3207-3216. PubMed ID: 33813646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]